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Abstract
The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR) and MET are activated in subsets
of mesothelioma, suggesting that these kinases might represent novel therapeutic targets in this notoriously
chemotherapy-resistant cancer. However, clinical trials have shown little activity for EGFR inhibitors in mesotheli-
oma. Despite the evidence for RTK activation in mesothelioma pathogenesis, it is unclear whether transforming
activity is dependent on an individual kinase oncoprotein or the coordinated activity of multiple kinases. Using
phospho-RTK and immunoblot assays, we herein demonstrate activation of multiple RTKs (EGFR, MET, AXL,
and ERBB3) in individual mesothelioma cell lines but not in normal mesothelioma cells. Inhibition of mesothe-
lioma multi-RTK signaling was accomplished using combinations of RTK direct inhibitors or by inhibition of the
RTK chaperone, heat shock protein 90 (HSP90). Multi-RTK inhibition by the HSP90 inhibitor 17-allyloamino-17-
demethoxygeldanamycin (17-AAG) had a substantially greater effect on mesothelioma proliferation and survival
compared with inhibition of individual activated RTKs. HSP90 inhibition also suppressed phosphorylation of down-
stream signaling intermediates (AKT, mitogen-activated protein kinase, and S6); upregulated the p53, p21, and
p27 cell cycle checkpoints; induced G2 phase arrest; induced caspase 3/7 activity; and led to an increase in the
sub-G1 apoptotic population. These compelling proapoptotic and antiproliferative responses indicate that HSP90
inhibition warrants clinical evaluation as a novel therapeutic strategy in mesothelioma.
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Introduction
Malignant mesothelioma is a locally aggressive and highly lethal neo-
plasm in which the neoplastic proliferation originates from pleural,
peritoneal, or, rarely, pericardial mesothelial cells [1]. Mesothelioma
has been linked to asbestos exposure [1], and epidemiologic studies
also show that mesothelioma risk increases after inhalation of the
airborne mineral dust, erionite [2]. In addition, some investigations
have implicated SV40 virus in the pathogenesis of a subset of meso-
theliomas [3]. Mesothelioma histologic subtypes include epitheli-
oid, spindle, or mixed (epithelioid and spindled) [1], of which the
spindled subtype generally has the worst prognosis. Mesothelioma
incidence increased after 1970, reflecting heavier worldwide occu-
pational asbestos exposure after World War II [4]. An estimated
3000 new cases per year are diagnosed in the United States, and most
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patients die within 1 year, with fewer than 5% of all patients cured,
even when intensive combined modality therapeutic strategies are
used. Conventional chemotherapies and radiation therapy have only
limited efficacy against mesothelioma, and improved survival will
presumably require development of novel and more effective pharma-
cological interventions. An improved understanding of mesothelioma
biology—including key growth factor signaling pathways—might be
useful in identifying biologically rational targets for novel therapies.
Various studies suggest that receptor tyrosine kinase (RTK) acti-
vation participates in the oncogenic progression of nonneoplastic
mesothelial progenitor cells to malignant mesothelioma. For exam-
ple, epidermal growth factor receptor (EGFR) is upregulated and
tyrosine-phosphorylated in some mesotheliomas, resulting in down-
stream activation of the mitogen-activated protein kinase (MAPK)
proliferation–associated signaling pathway [5,6], and implicating
EGFR activation in asbestos-induced mesothelial mitogenicity and
carcinogenesis. Furthermore, gefitinib, a specific EGFR small molec-
ular inhibitor, inhibits EGFR-mediated AKT and MAPK phosphor-
ylation, and inhibits proliferation in some mesothelioma cell lines
[7]. The MET RTK protein and its ligand (hepatocyte growth factor)
are co-overexpressed in mesothelioma compared with nonneoplastic
mesothelial cells [8,9], and MET activation induces mesothelioma
cell proliferation [9]. Furthermore, intragenic MET point mutations
have been reported in a minority of mesotheliomas [10]. The MET
inhibitor, PHA-665752, causes cell cycle arrest and decreased phos-
phorylation of MET, p70S6K, AKT, and MAPK in mesothelioma cell
lines [11], and likewise MET inhibition by the small molecule inhib-
itor, SU11274, or by RNAi knockdown, inhibits mesothelioma cell
line proliferation [10]. SV40 infection might contribute to autocrine
mechanisms of MET activation in mesothelioma, thereby providing
an intriguing connection between mesothelioma pathogenesis and
potential drug targets [12]. In addition, the RTK EPHB4 is highly
expressed in mesothelioma but not in normal mesothelial cells.
EPHB4 knockdown is associated with inhibition of mesothelioma
cell proliferation, migration, and invasion, accompanied by caspase-
8–mediated apoptosis and down-regulation of the antiapoptotic
protein Bcl-xl [13]. Vascular endothelial growth factor receptor 1/2
intratumoral tyrosine kinase activation, in addition to facilitating me-
sothelioma angiogenesis and lymphangiogenesis [14], might directly
regulate mesothelioma cell proliferation [15]. Insulin-like growth
factor 1 (IGF-1) and IGF-1R, although expressed at comparable lev-
els in nonneoplastic and malignant mesothelial cells [16], might also
contribute to mesothelioma development, as evidenced by the con-
sequences of IGF-1R inhibition, which inhibits mesothelioma pro-
liferation and tumorigenicity [17].
Despite the previously mentioned evidence for tyrosine kinase acti-
vation in mesothelioma pathogenesis, targeted tyrosine kinase inhibitor
(TKI) therapies have not had dramatic clinical success in mesothelioma.
This is surprising, given the many examples of tyrosine kinase inhibitor
therapeutic successes in human cancers, including targeting of HER2
in metastatic breast cancer [18], KITand platelet-derived growth factor
receptor A in gastrointestinal stromal tumors [19], ABL in chronic
myelogenous leukemia [20], and EGFR in non–small cell lung cancer
[21]. In the present studies, we demonstrate coactivation of multiple
RTKs—including EGFR, ERBB3, MET, and AXL—in individual me-
sothelioma cell lines. We also demonstrate that heat shock protein 90
(HSP90) inhibition inactivates these multiple RTKs in a given meso-
thelioma, thereby maximizing proapoptotic and antiproliferative effects
compared with the consequences of inactivating any single RTK in a
given mesothelioma.
Materials and Methods
Antibodies and Reagents
Monoclonal antibody to EGFR (immunoprecipitation), phospho-
tyrosine (PY99), and p53 and polyclonal antibodies to EGFR, MET,
and AXL were from Santa Cruz Biotechnology (Santa Cruz, CA).
Polyclonal antibodies to AKT and cleaved caspase 3 were from Cell
Signaling Technology (Beverly, MA). Antibodies to MAPK and p21
Figure 1. Coactivation of multiple RTKs in mesothelioma cell lines. (A) Total cell lysates (500 μg) from MESO924 cells grown for 2 hours
in serum-containing (FBS+) or serum-free (FBS−) medium were analyzed by phospho-RTK array. Each RTK is spotted in duplicate, and
the spots at each corner are positive controls, whereas eight spots at the lower right are negative controls. (B) Total cell lysates (500 μg)
from normal mesothelial cells grown for 2 hours in serum-free medium analyzed by phospho-RTK array. (C) Immunoblot evaluations of
EGFR, ERBB3, MET, and AXL in MESO924 versus nonneoplastic mesothelial cells. Actin stain is a loading control.
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were from Zymed/Invitrogen Laboratories (Invitrogen life Technol-
ogies, Carlsbad, CA). Phospho-specific antibodies and monoclonal
antibody to S6 were from Cell Signaling Technology. Antibodies to
ERBB3, p27, and β-actin were from NeoMarkers (Fremont, CA),
BD Transduction Laboratories (San Jose, CA), and Sigma-Aldrich
(St Louis, MO), respectively.
Human Phospho-RTK Array Kit was from R&D Systems (Min-
neapolis, MN). 17-Allyloamino-17-demethoxygeldanamycin (17-
AAG) and gefitinib were obtained from LC Labs (Woburn, MA),
and PHA-665752 was from Tocris Biosciences (St Louis, MO).
DP-3975 was obtained from Deciphera Pharmaceuticals (Lawrence,
KS). All inhibitors were reconstituted in DMSO. Protein A– and
Figure 2. (A) Immunoblot analysis quantitations of EGFR, MET, and AXL expression in mesothelioma cells versus nonneoplastic meso-
thelial cells (HM3). The expression quantitations (lower panel) were normalized to the HM3 cells. (B) EGFR, MET, and AXL activation in
mesothelioma cells was validated by immunoprecipitation of each kinase followed by phosphotyrosine immunoblot analysis.
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protein G–sepharose beads were purchased from Zymed Laboratories
(Invitrogen Life Technologies).
Novel Mesothelioma Cell Lines
Ten mesothelioma cell lines were established from surgical materials
in previously untreated patients. These studies were approved by the
Brigham andWomen’sHospital Institutional ReviewBoard, under a dis-
carded tissues protocol. The MESO257 and MESO924 cell lines were
established from epithelial-type mesotheliomas, whereas MESO296,
MESO346,MESO507,MESO542,MESO647, andMESO1413were
from mixed-histology mesotheliomas, and MESO188 and MESO428
were from spindle cell mesotheliomas. Derivation of each cell line
from the corresponding surgical specimen was corroborated by dem-
onstrating persistence of unique clonal cytogenetic aberrations—as
seen in the primary tumors—in each of the cell lines (data not shown).
The normal mesothelial cells in the phospho-RTK arrays were es-
tablished in our laboratory, from a nonneoplastic pleural effusion.
The normal mesothelial cells in the immunoblot analysis studies were
established from nonneoplastic peritoneum, as described previously
[22]. Mesothelioma cell lines were maintained in RPMI 1640 with
15% fetal bovine serum (FBS) containing penicillin/streptomycin and
L-glutamine. Normal mesothelial cells were cultured in F10 contain-
ing 15% FBS, penicillin/streptomycin, L-glutamine, amphotericin,
MitoTracker (BDBiosciences, Bedford,MA), and bovine pituitary extract.
Phospho-RTK Array Analysis
The Human Phospho-RTK Array Kit (R&D Systems) was used to
determine the relative levels of tyrosine phosphorylation of 42 dis-
tinct RTKs, according to the manufacturer’s protocol. Briefly, meso-
thelioma cell lines were maintained in RPMI 1640 medium with
15% fetal bovine serum containing penicillin/streptomycin and
L-glutamine. After incubating with DMSO versus 1 μM 17-AAG
in serum-free medium for 6 hours, cell line lysates were prepared
using lysis buffer (1% NP-40, 50 mM Tris-HCl pH 8.0, 100 mM
Figure 3. (A) Cell viability determined by the CellTiter-Glo ATP–based luminescence assay in mesothelioma cell lines after 72 hours of
treatment with inhibitors of EGFR (1 μM gefitinib), MET (1 μM PHA-665752), AXL (1 μM DP-3975), and HSP90 (1 μM 17-AAG). Data were
normalized to the DMSO control, and shown are mean values (±SD) of quadruplicate cultures. (B) Phospho-RTK arrays show concurrent
inactivation of multiple RTKs in mesothelioma cell lines. After treatment with 17-AAG (1 μM) for 6 hours in serum-free medium, phos-
phorylation quantitations (lower panel) were normalized to the negative controls.
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sodium fluoride, 30 mM sodium pyrophosphate, 2 mM sodium
molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) containing
protease inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, and
1 mM phenylmethylsulfonyl fluoride). The arrays were incubated
with 500 μg of protein lysate overnight at 4°C after blocking for 1 hour
with Array Buffer 1 (R & D Systems, Minneapolis, MN). The arrays
were washed and incubated with a horseradish peroxidase–conjugated
phospho-tyrosine detection antibody (1:5000). Detection was by chemi-
luminescence (Immobilon Western, Millipore Corporation, MA), and
signals were captured using a FUJI LAS 1000-plus chemiluminescence
imaging system. The intensity of each phospho-RTK array signal was
quantitated by an image analyzer (FUJIFILM MultiGauge; Fuji Film,
Tokyo, Japan), and relative intensities of the averaged signal from each
pair of duplicated spots were determined in relationship to the negative
control spots.
Protein Lysate Preparations and Immunoblot Analysis
Immunoblot evaluations of signaling pathway expression and ac-
tivation were performed after incubating cells for 6 hours with kinase
inhibitors or 17-AAG in a serum-free medium. Immunoblot evalua-
tions of apoptosis and cell cycle biomarkers were evaluated after drug
treatments in serum-containing medium for 48 hours. Lysates were
rocked overnight at 4°C, and the supernatants were collected after
microcentrifuging at 14,000 rpm for 20 minutes at 4°C. Protein con-
centrations were determined by the Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA). Electrophoresis and immunoblot analysis
were performed as described previously [23], with hybridization signals
detected by chemiluminescence (Amersham Pharmacia Biotechnology,
Little Chalfont, UK) and captured using a FUJI LAS1000-plus chemi-
luminescence imaging system (Fuji Film, Tokyo, Japan).
Immunoprecipitation Evaluations of EGFR, MET, and
AXL Activation
One milligram of protein lysate (500 μl) was preadsorbed for
30 minutes using 20 μl of protein G or protein A beads at 4°C.
Sepharose–protein G beads were used for mouse monoclonal anti-
body and goat polyclonal antibody, whereas sepharose–protein A
beads were used for rabbit polyclonal antibody. Two micrograms of
EGFR, MET, or AXL antibody was added to the supernatants and
rocked for 2 hours at 4°C. Twenty microliters of sepharose–protein G
or protein A beads was added and rocked overnight at 4°C. Beads
were collected by centrifugation in a microcentrifuge at 10,000 rpm
for 2 minutes at 4°C, washed three times (25 minutes for each wash)
with 750 μl of immunoprecipitation (IP) buffer, followed by one wash
in 750 μl of 10 mM Tris-HCl buffer (pH 7.6). Twenty microliters
of loading buffer was added to the beads and boiled for 5 minutes at
97°C. EGFR, MET, and AXL activation and expression were evaluated
by immunoblot analysis.
Cell Proliferation and Apoptosis Assays
MESO924, MESO257, MESO296, and MESO428 cells were
plated in a 96-well flat-bottomed plate (Falcon, Lincoln, NJ) and cul-
tured for 24 hours before being treated with gefitinib (1 μM), PHA-
665752 (1 μM), DP-3975 (1 μM), alone or in combination, and
with 17-AAG (0.1, 0.25, 0.5, 0.75, and 1 μM). Cell viability and
apoptosis were determined using the CellTiter-Glo and Caspase-
Glo 3/7 assays, respectively (Promega, Madison, WI), and measured
Figure 3. (continued).
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using a VeritasMicroplate Luminometer (Turner Biosystems, Sunnyvale,
CA). Data were normalized to the control group (DMSO). All ex-
perimental points were set up in four replicate wells and indepen-
dently performed in duplicate.
Cell Cycle Analysis
MESO924,MESO257, MESO296, andMESO428 cells in six-well
plates were treated with inhibitors for 48 hours, then trypsinized and
washed once with Hank’s balanced salt solution. For nuclear staining,
a 4′-6-diamidino-2-phenylindole (DAPI)-containing solution (Nuclear
Isolation and Staining Solution; NPE Systems, Pembroke Pines, FL)
was added to the cells, and the cell suspension was immediately ana-
lyzed in a flow cytometer (NPE Quanta; NPE Systems) using ModFit
LT software 3.1 (Verity Software House, Topsham, ME).
Results
Expression of Multiple Activated RTKs in Mesothelioma
Phospho-RTK array assays, in MESO924 malignant mesothe-
lioma cells, demonstrated coordinated activation of RTKs EGFR,
ERBB3, AXL, and MET, irrespective of whether the cells were eval-
uated in serum-containing or serum-free conditions (Figure 1A).
However, IGF-1R was activated only in serum-containing conditions
(Figure 1A). By contrast, phospho-RTK array of normal mesotheli-
oma cells in serum-free conditions demonstrated apparent activation
of EGFR, only, among the RTKs (Figure 1B), and this finding was
not corroborated by immunoblot analysis (Figure 1C ), indicating
that the array phopsho-EGFR expression was a false-positive result.
Likewise, we found, in validations of other human cancers, that the
phospho-array EGFR activation signal was overly sensitive (data not
shown). The immunoblot assays demonstrated that EGFR, MET,
ERBB3, and AXL activation, in MESO924, resulted in part from
a higher expression of each of these kinases, compared with the ex-
pression levels in the normal mesothelial cells (Figure 1C ).
Validation studies confirmed a strong expression of EGFR, MET,
and AXL in a large panel of mesothelioma cell lines but not in nor-
mal mesothelial cells (Figure 2A). EGFR, MET, and AXL were co-
expressed in most mesothelioma cell lines at levels two- to five-fold
higher than in the normal mesothelial cells (Figure 2A). In addition,
phosphotyrosine characterizations demonstrated that EGFR, MET,
and AXL were coordinately activated in the mesothelioma cell lines
(Figure 2B).
Consequences of Single Versus Combination Tyrosine Kinase
Inhibitor Treatments on Mesothelioma Viability
Inhibitors of EGFR (gefitinib), MET (PHA-665752), and AXL
(DP-3975) were evaluated singly and in combination and were con-
trasted with HSP90 inhibitor (17-AAG) treatment, in novel low-
passage mesothelioma cell lines (Figure 3A). In all mesothelioma cell
lines, the greatest reduction in cell viability (>40%) was achieved by
coordinated inhibition of EGFR, MET, and AXL, either through use
of multiple kinase inhibitors or by HSP90 inhibition (Figure 3A).
EGFR and MET inhibition, whether singly or in combination,
had little effect on mesothelioma viability (Figure 3A). AXL inhibi-
tion resulted in 60% reduction of mesothelioma cell viability in
MESO257, but with lesser effects in the other cell lines, whereas
combined AXL and EGFR inhibition resulted in greater than 40%
reduction in viability for all cell lines (Figure 3A).
Inactivation of Multi-RTKs and Downstream Intermediates by
HSP90 Inhibition
The observation that individual RTK inhibitors have little effect
on mesothelioma cell viability (Figure 3A) suggested that activation
of any one RTK is insufficient to sustain mesothelioma growth and/
Figure 4. Inactivation of multiple RTKs and signaling intermediates by HSP90 inhibition. (A) EGFR, AXL, and MET phosphorylation in cell
immunoprecipitates after 6 hours of 17-AAG treatment in serum-free medium. (B) EGFR, ERBB3, MET, AKT, S6, and MAPK phosphor-
ylation after 6 hours of 17-AAG treatment in serum-free medium. β-Actin stain is a loading control.
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or survival. Therefore, we hypothesized that inactivation of multiple
RTKs by HSP90 inhibition might inhibit mesothelioma growth and
survival mechanisms, including phosphoinositide 3-kinase (PI3-K)/
AKT and MEK/MAPK signaling [10,11]. This possibility is supported
by published evidence that EGFR and MET are activated in many
mesotheliomas [7,10,11] and evidence that HSP90 has crucial roles in
maintaining conformation and stability of many activated RTKs, in-
cluding EGFR and MET [24].
HSP90 inhibition by 17-AAG treatment in MESO924 and
MESO428 inactivated EGFR, MET, ERBB3, AXL, EPHA7, and
EPHB2, as shown by tyrosine kinase phosphorylation quantitations
(Figure 3B). EGFR, MET, and AXL inactivation, in 17-AAG–treated
mesothelioma cells, was confirmed by immunoprecipitation and phospho-
tyrosine (PY99) immunostaining (Figure 4A), and EGFR, MET, and
ERBB3 inactivation were further validated by phospho-immunoblot
analysis of mesothelioma total cell lysates (Figure 4B). As expected,
HSP90 inhibition induced degradation of these tyrosine kinases,
as evidenced by the reduction of total EGFR, MET, and AXL
expression after 48 hours of 17-AAG treatment (Figure 5A). AKT
and S6 were substantially and dose-dependently inactivated in all
Figure 4. (continued).
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mesothelioma cell lines after HSP90 inhibition, whereas MAPK
was inactivated in two of the mesothelioma lines (MESO296 and
MESO428; Figure 4B).
HSP90 Regulation of Mesothelioma Proliferation and Survival
Cell proliferation, as assessed using an ATP-based cell viability assay
(CellTiter-Glo), was strongly inhibited in all mesothelioma cell lines
after HSP90 inhibition (Figure 6A): 17-AAG half maximal inhibitory
concentration (IC50) values in mesotheliomas with spindle-cell com-
ponents, MESO296 and MESO428, were 69 and 72 nM, respectively,
and in epithelioid mesotheliomas, MESO257 and MESO924, were
192 and 266 nM, respectively. These data suggest that HSP90 regula-
tion of mesothelioma cell viability can be targeted effectively in poor-
prognosis spindle-cell mesotheliomas.
HSP90 inhibition induced mesothelioma apoptosis, as evidenced
by caspase 3 cleavage (Figure 5B), and heightened caspase 3/7 activity
(Figure 6B). These 17-AAG effects were particularly prominent in
MESO296, which also had the most nuclear fragmentation after
17-AAG treatment (Figure 6C and Table W1). HSP90 inhibition
induced up-regulation of p27, p21, and p53 cell cycle checkpoint
proteins (Figure 5B), which was accompanied by cell cycle arrest
(Figure 6C and Table W1).
Cell cycle analyses demonstrated dose-dependent G2 block with
decreased S-phase population after HSP90 inhibition by 17-AAG
(Figure 6C and Table W1). HSP90 inhibition induced apoptosis,
as evidenced by nuclear fragmentation in all mesothelioma lines (Fig-
ure 6C : blue sub-G1 peak). Fragmented/apoptotic cells, in MESO924,
MESO257, MESO296, and MESO428 treated with DMSO-only
control versus 0.5 μM 17-AAG were 0.1% versus 8.0%, 1.7% versus
4.4%, 1.7% versus 20%, and 0.7% versus 2.6%, respectively (Fig-
ure 6C and Table W1).
Discussion
Available therapies, including surgery, radiation, and chemotherapy,
have not substantially improved survival for patients with mesothe-
lioma. Hence, there is an urgent need to validate novel and biologically
rational therapies for this invariably lethal disease. Tyrosine kinase pro-
teins regulate cell proliferation and survival in many human cancers
[25], and there is increasing evidence that tyrosine kinase activation
promotes biologic progression from nonneoplastic mesothelial progen-
itor cells to malignant mesothelioma. The studies reported here show
that multiple RTKs are coactivated and coexpressed in an HSP90-
dependent manner in individual mesothelioma populations, whereas
these kinases are not strongly activated in normal mesothelial cells.
The activated tyrosine kinases contribute collectively to mesothelioma
PI3-K/AKT survival and proliferation signaling, suggesting that inhibi-
tors of HSP90-mediated kinase chaperone functions might be useful
therapeutic strategies in mesothelioma.
Our studies—using novel and histologically representative meso-
thelioma cell lines—are consistent with recent clinical evidence that
inhibitors of individual activated tyrosine kinases generally do not
induce major therapeutic responses in mesothelioma [26,27]. We
Figure 5. Effects of HSP90 inhibition (17-AAG) in mesothelioma cell lines by 17-AAG treatment for 48 hours in serum-containing me-
dium. (A) EGFR, AXL, and MET expression. (B) p27, p53, and p21 expression and cleavage of apoptosis biomarker caspase 3. β-Actin is a
loading control.
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demonstrate activation and expression of multiple RTKs in indi-
vidual mesotheliomas but not in normal mesothelial cells (Figures 1
and 2). These studies suggest that the coordinated activation of
multiple RTKs (including EGFR, MET, ERBB3, and AXL) in meso-
theliomas might enable resistance to drugs targeting single RTKs.
Hepatocyte growth factor/METsignaling has been implicated in me-
sothelioma pathogenesis, with this ligand/receptor pair co-ordinately
overexpressed [8] and contributing to invasiveness and prolifera-
tion [9,28]. In addition, MET oncogenic mutations have been iden-
tified in a subset of mesotheliomas [10], and the MET inhibitors,
SU11274 and PHA-665752, and MET knockdown by RNAi, exert
antiproliferative effects in mesothelioma cell lines by inhibiting MET-
dependent PI3-K/AKTand RAF/MAPK signaling pathways, culminat-
ing in cell cycle arrest [10,11]. In the present study, neither did a MET
inhibitor, PHA-665752, substantially antagonize mesothelioma viabil-
ity (Figure 3A) nor did PHA-665752 inhibition of viability correlate
with baseline MET tyrosine phosphorylation in the mesotheliomas
(Figures 1 and 2B). Similarly, only minor reductions in mesothelioma
viability were observed after gefitinib-mediated EGFR inhibition, and
these effects did not correlate with baseline EGFR tyrosine phosphor-
ylation (Figures 1 and 2B), although EGFR was expressed strongly
(Figure 2A) [5,7,29]. Our findings are in keeping with the lack of
gefitinib activity in a phase 2 mesothelioma trial [26]. Although acti-
vation of EGFR and METwas completely inhibited by gefitinib and
PHA-665752 (data not shown), antiproliferative effects after combined
inhibition of EGFR andMETwere no greater than those observed after
inhibition of either of these kinases, individually (Figure 3A). Other
recent studies have shown that combined EGFR and MET inhibition
can suppress mesothelioma proliferation, although it is not clear that
the high drug concentrations responsible for such effects can be
achieved clinically [30].
Using phosphotyrosine immunopurification, we have demonstrated
AXL tyrosine kinase activation in mesotheliomas (Ou and Fletcher,
unpublished observations). AXL has transforming activity in other
human cancers [31,32], and herein we show that AXL inactivation
inhibited mesothelioma viability by 20% to 50%, whereas the com-
bination of EGFR, MET, and AXL inactivation inhibited viability by
40% to 60% (Figure 3A).
Figure 6. HSP90 regulation of mesothelioma proliferation and survival. (A) Mesothelioma cell viability (CellTiter-Glo assay) after 17-AAG
treatment for 72 hours in serum-containing medium. Data were normalized to the DMSO control, and shown are mean values (±SD) of
quadruplicate cultures. (B) Apoptosis after 17-AAG treatment for 24 hours in serum-containing medium. Caspase 3/7 activity was mea-
sured using a Caspase-Glo luminescence assay. Data were normalized to the DMSO control, and shown are mean values (±SD) from
quadruplicate cultures. (C) Cell cycle analyses after 17-AAG treatment for 48 hours in serum-containing medium.
20 RTK Inhibition in Mesothelioma Ou et al. Neoplasia Vol. 13, No. 1, 2011
Many activated RTKs are dependent on HSP90-mediated chaper-
one functions, and we therefore hypothesized that HSP90 inhibition
might interfere with the multi-RTK activation in mesothelioma.
HSP90 optimizes and maintains folding and localization for many
activated tyrosine kinases and also prevents their proteasomal degra-
dation [24]. HSP90 is an abundant protein in eukaryotic cells, com-
prising up to 1% to 2% of the total cellular protein, and has key roles
in regulating cell proliferation, differentiation, and apoptosis [33,34].
The HSP90 inhibitor 17-AAG, a geldanamycin derivative [35],
binds a conserved ATP interaction pocket in the HSP90 NH2-
terminal domain [36] and has activity against various human cancers
in preclinical models, where it can be highly selective in degrading
HSP90-client oncoproteins [37,38]. Whereas 17-AAG clinical appli-
cations have been hampered by its low water solubility, IPI-504, a
17-AAG derivative, exhibits improved aqueous solubility while main-
taining the biologic HSP90-inhibitory properties of 17-AAG [39].
Furthermore, clinical trials are ongoing, in various cancer types, with
new-generation synthetic HSP90 inhibitors. Additional studies are
needed to determine which HSP90 inhibitors are most effective as
mesothelioma multi-RTK inhibitors and to determine whether the
compelling in vitro mesothelioma responses reported herein are
achievable using in vivo models.
HSP90 inhibition by 17-AAG reduced cell viability dramatically
(Figure 6A) in all mesothelioma cell lines and was associated with
AKT and S6 inhibition (Figure 4B). Notably, 17-AAG inhibition
of mesothelioma viability has also been reported, recently, in a differ-
ent panel of mesothelioma cell lines [40], although biochemical cor-
relates for 17-AAG treatment were not evaluated. In the studies
performed herein, HSP90 inhibition was associated with concurrent
AKTand MAPK inactivation in MESO296 and MESO428, whereas
in the other mesothelioma lines, MAPK was not inactivated despite
AKT inactivation (Figure 4B). These observations suggest that
MAPK activation might not be HSP90-dependent in all mesotheli-
omas, or alternately, different HSP90 clients might both activate and
inactivate MAPK, such that HSP90 inhibition results in little net
change in MAPK phosphorylation. In keeping with these signaling
perturbations, dose-dependent 17-AAG inhibition of the EGFR,
MET, and ERBB3 RTKs was demonstrated by staining Western
blots with phospho-specific antibodies and showed coordinate inacti-
vation of EGFR, MET, and ERBB3 in all mesotheliomas (Figure 4B).
The effects of 17-AAG on AXL, EGFR, and MET activation were
also evaluated by phospho-RTK array assays and by immunopre-
cipitation of each of these kinase proteins, followed by immunoblot
analysis for phosphotyrosine (Figures 3B and 4A). These studies con-
firmed coordinate AXL, EGFR, and MET inactivation, after HSP90
inhibition, in all mesothelioma cell lines (Figure 4A). HSP90 in-
hibition reduced cell viability dramatically in each mesothelioma
cell line (Figure 6A). Forty-eight-hour treatments with 17-AAG, in
serum-containing medium, were associated with AXL, EGFR, and
MET degradation in all cell lines (Figure 5A), accompanied by up-
regulation of the cell cycle checkpoint inhibitors p21, p27, and p53
and caspase 3 cleavage (Figure 5B). Notably, higher levels of p21
and p27 expression are associated with improved survival in mesothe-
lioma [41,42].
In conclusion, these studies demonstrate that mesothelioma cell
proliferation and survival require coactivation of multiple RTKs, in-
cluding EGFR, MET, and AXL. Signaling pathways dependent on
these collective activated kinases can be antagonized by treatment with
HSP90 inhibitors, which inactivate the kinases or block downstream
survival/proliferation signaling. Hence, HSP90 inhibition, whether as
a single agent or combination therapy, warrants evaluation as a novel
therapeutic strategy in mesothelioma.
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Table W1. Cell Cycle Analyses (%), as Shown in Figure 6C, after 17-AAG Treatment.
Inhibitor MESO924 MESO257 MESO296 MESO428
G1/0 G2 S A G1/0 G2 S A G1/0 G2 S A G1/0 G2 S A
DMSO 59 10 31 0.1 58 6 36 1.7 60 10 30 1.7 63 3 34 0.7
17-AAG (0.1 μM) 59 30 11 3.8 64 13 23 1.0 60 9 31 23 61 7 31 2.2
17-AAG (0.5 μM) 41 43 16 8.0 28 68 4 4.4 68 9 23 20 57 39 4 2.6
17-AAG (1 μM) 35 54 11 11 29 68 3 3.7 59 27 14 23 55 42 3 4.1
A indicates apoptosis before G1 peak.
